S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches

RXi Pharmaceuticals (RXII) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

RXII vs. ARTL, PTIX, KTRA, KZIA, FWBI, PTPI, ARDS, THAR, GOVX, and BPTS

Should you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include Artelo Biosciences (ARTL), Protagenic Therapeutics (PTIX), Kintara Therapeutics (KTRA), Kazia Therapeutics (KZIA), First Wave BioPharma (FWBI), Petros Pharmaceuticals (PTPI), Aridis Pharmaceuticals (ARDS), Tharimmune (THAR), GeoVax Labs (GOVX), and Biophytis (BPTS). These companies are all part of the "medical" sector.

RXi Pharmaceuticals vs.

Artelo Biosciences (NASDAQ:ARTL) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.

Artelo Biosciences has higher earnings, but lower revenue than RXi Pharmaceuticals. Artelo Biosciences is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$10.08M-$3.33-0.44
RXi Pharmaceuticals$10K419.69-$12.45M-$4.20-0.23

In the previous week, Artelo Biosciences had 2 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 2 mentions for Artelo Biosciences and 0 mentions for RXi Pharmaceuticals. RXi Pharmaceuticals' average media sentiment score of 1.43 beat Artelo Biosciences' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Artelo Biosciences Positive
RXi Pharmaceuticals Neutral

Artelo Biosciences has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, RXi Pharmaceuticals has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.

RXi Pharmaceuticals received 156 more outperform votes than Artelo Biosciences when rated by MarketBeat users. However, 72.00% of users gave Artelo Biosciences an outperform vote while only 68.09% of users gave RXi Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Artelo BiosciencesOutperform Votes
36
72.00%
Underperform Votes
14
28.00%
RXi PharmaceuticalsOutperform Votes
192
68.09%
Underperform Votes
90
31.91%

Artelo Biosciences currently has a consensus price target of $32.50, suggesting a potential upside of 2,110.88%. Given RXi Pharmaceuticals' higher possible upside, equities analysts clearly believe Artelo Biosciences is more favorable than RXi Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
RXi Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

1.4% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 9.6% of RXi Pharmaceuticals shares are owned by institutional investors. 6.9% of Artelo Biosciences shares are owned by company insiders. Comparatively, 1.0% of RXi Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Artelo Biosciences has a net margin of 0.00% compared to Artelo Biosciences' net margin of -4,990.20%. RXi Pharmaceuticals' return on equity of -56.30% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -56.30% -53.62%
RXi Pharmaceuticals -4,990.20%-412.15%-179.54%

Summary

Artelo Biosciences beats RXi Pharmaceuticals on 11 of the 16 factors compared between the two stocks.


Get RXi Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXII vs. The Competition

MetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$4.20M$6.93B$5.05B$7.61B
Dividend YieldN/A2.81%2.81%3.87%
P/E Ratio-0.2319.08268.4718.95
Price / Sales419.69216.093,019.5373.94
Price / CashN/A19.0798.1954.91
Price / Book1.244.944.594.72
Net Income-$12.45M$162.80M$114.93M$211.49M

RXi Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARTL
Artelo Biosciences
3.2959 of 5 stars
$1.55
+2.6%
$32.50
+1,996.8%
-48.1%$4.43MN/A-0.475Short Interest ↓
PTIX
Protagenic Therapeutics
0 of 5 stars
$0.88
flat
N/A+144.2%$3.90MN/A0.00N/AShort Interest ↓
KTRA
Kintara Therapeutics
0.3232 of 5 stars
$0.10
flat
N/A-97.9%$3.90MN/A-0.022Short Interest ↑
Gap Down
KZIA
Kazia Therapeutics
3.4363 of 5 stars
$0.28
-6.7%
$2.00
+616.8%
-74.6%$4.56M$20,000.000.002,021Short Interest ↓
FWBI
First Wave BioPharma
2.8352 of 5 stars
$6.85
+15.3%
$120.00
+1,651.8%
-87.1%$4.66MN/A-0.0310Short Interest ↓
PTPI
Petros Pharmaceuticals
2.7407 of 5 stars
$1.66
+5.1%
$4.00
+141.0%
-16.5%$3.65M$5.99M0.0024Gap Up
ARDS
Aridis Pharmaceuticals
0.4944 of 5 stars
$0.08
flat
$2.00
+2,566.7%
-85.5%$3.60M$3.09M-0.4737
THAR
Tharimmune
2.7369 of 5 stars
$0.41
+7.9%
N/AN/A$4.83MN/A-0.031Short Interest ↓
GOVX
GeoVax Labs
2.9842 of 5 stars
$2.71
+14.8%
$90.00
+3,221.0%
-75.5%$4.83M$80,000.00-0.2014Short Interest ↑
News Coverage
High Trading Volume
BPTS
Biophytis
2.8918 of 5 stars
$0.50
-3.8%
$15.00
+2,900.0%
-89.0%$4.87MN/A0.0026Short Interest ↓
Gap Down

Related Companies and Tools

This page (NASDAQ:RXII) was last updated on 3/2/2024 by MarketBeat.com Staff